We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RT-PCR Database Analysis for COVID-19 Infections and Re-infection (ReCOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04653844
Recruitment Status : Recruiting
First Posted : December 4, 2020
Last Update Posted : January 4, 2022
Sponsor:
Collaborators:
Laboratoire CERBA-MPL
CNRS (MIVEGEC)
Nîmes University Hospital
Information provided by (Responsible Party):
University Hospital, Montpellier

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection. We propose to analyze a large set of laboratory data produced since the early beginning of the SARS-Cov2 spread in the French population to identify recurrent infection events and, more generally, gain insight about infection kinetics.

Condition or disease
Covid-19 SARS-CoV Infection

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 7000000 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database
Actual Study Start Date : February 1, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : January 30, 2023

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. SARS-CoV-2 reinfection rate [ Time Frame: 1 day ]
    SARS-CoV-2 reinfection rate


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
French population with a positive SARS-Cov2 diagnosis documented through a positive RT-PCR result
Criteria

Inclusion criteria:

- People with at least one positive SARS-Cov2 RT-PCR result with a known sampling date

Exclusion criteria:

- Patient refusing to participate in research

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04653844


Contacts
Layout table for location contacts
Contact: Samuel Alizon, PhD 610654902 ext 33 samuel.alizon@cnrs.fr
Contact: Vincent Foulongne, PhD 467 330 254 ext 33 v-foulongne@chu-montpellier.fr

Locations
Layout table for location information
France
Uh Montpellier Recruiting
Montpellier, France, 34295
Contact: Vincent Foulongne, PHD    467 330 254 ext 33    v-foulongne@chu-montpellier.fr   
Sponsors and Collaborators
University Hospital, Montpellier
Laboratoire CERBA-MPL
CNRS (MIVEGEC)
Nîmes University Hospital
Investigators
Layout table for investigator information
Study Director: Vincent Foulongne, PhD UH MONTPELLIER
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT04653844    
Other Study ID Numbers: RECHMPL20_0640
First Posted: December 4, 2020    Key Record Dates
Last Update Posted: January 4, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier:
SARS-Cov2 infection
Positive SARS-Cov2 RT-PCR
SARS-Cov2 immune status
reinfection
 kinetics
Rt-PCR
immunity
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Communicable Diseases
Severe Acute Respiratory Syndrome
Disease Attributes
Pathologic Processes
Respiratory Tract Infections
Pneumonia, Viral
 Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases